logo
Plus   Neg
Share
Email

Gilead Sciences Receives Approval In Canada For Yescarta

Gilead Sciences Canada, Inc. said that Health Canada has granted a Notice of Compliance or NOC for Yescarta (axicabtagene ciloleucel), a new chimeric antigen receptor T (CAR T) cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL.

YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma.

YESCARTA is a CAR T cell therapy, also known as a form of immunotherapy, that is custom-made for each patient from his or her own T cells - a type of white blood cell that is part of the immune system and that recognizes and kills foreign cells.

The process works by removing the patient's T cells and genetically altering them with chimeric antigen receptors (CARs). Once reinfused into the patient, the CAR T cells are able to find and attack cancer cells that normal T cells cannot detect.

This cell therapy induces complete response (no detectable cancer) in a proportion of patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma, which are aggressive forms of non-Hodgkin lymphoma (NHL).

YESCARTA will be manufactured by Kite, a Gilead Company (Kite) at its commercial manufacturing facility in El Segundo, California. In the ZUMA-1 pivotal trial, Kite demonstrated a 99 per cent manufacturing success rate with a median manufacturing turnaround time of 171 days.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018. Shares of BMW Group declined around 5 percent in German trading after the auto giant reported Wednesday weak profit in its fiscal year 2018, despite a 0.1 percent growth in Automotive revenues with higher deliveries. Looking ahead for fiscal 2019, the company expects Group profit before tax will be well below the previous year's level. BMW said it is confident of volume growth in Automotive unit. Starbucks Inc. has announced changes to its Starbucks Rewards loyalty program, noting that the revamp will provide its members with more flexibility and choice when they redeem stars at the company's stores. Starting on April 16, all members of the Starbucks Rewards loyalty program will be able to earn and redeem Stars for Rewards immediately after they join the program.
Follow RTT